This inventor holds 5 USPTO granted patents and 9 published patent applications. Top assignee: Genentech, Inc.. Active years: 2025-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025-2026
Title: Carol Elaine O'hear: Innovator in Bispecific Antibody Treatments
Introduction
Carol Elaine O'hear is a prominent inventor based in South San Francisco, CA. She has made significant contributions to the field of biotechnology, particularly in the development of bispecific antibodies for the treatment of various disorders. With a total of 5 patents, her work has the potential to impact the lives of many patients suffering from CD20-positive cell proliferative disorders.
Latest Patents
O'hear's latest patents include innovative methods for treating subjects with CD20-positive cell proliferative disorders. The first patent focuses on dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies. This invention specifically addresses the treatment of subjects with CD20-positive disorders, such as non-Hodgkin's lymphomas, through intravenous administration of an anti-CD20/anti-CD3 bispecific antibody, exemplified by mosunetuzumab. The second patent outlines methods for treating CD20-positive proliferative disorders using a combination of mosunetuzumab and polatuzumab vedotin. This combination therapy aims to enhance treatment efficacy for patients with these challenging conditions.
Career Highlights
Carol Elaine O'hear is currently associated with Genentech, Inc., a leading biotechnology company known for its innovative approaches to drug development. Her work at Genentech has allowed her to collaborate with some of the brightest minds in the industry, further advancing her research and inventions.
Collaborations
Some of her notable coworkers include Yasuhiro Oki and Iris Tranthuyngan To. Their collaborative efforts contribute to the ongoing research and development of groundbreaking therapies in the field of biotechnology.
Conclusion
Carol Elaine O'hear's contributions to the field of bispecific antibodies exemplify the innovative spirit of modern biotechnology. Her patents and work at Genentech, Inc. highlight her commitment to improving treatment options for patients with CD20-positive cell proliferative disorders.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile